A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally Daily to Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2014
At a glance
- Drugs XL 281 (Primary)
- Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors Exelixis
- 11 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 May 2010 Planned number of patients changed from 160 to 180 as reported by ClinicalTrials.gov.